 Connection
Ajay Major to Aged
This is a "connection" page, showing publications Ajay Major has written about Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.444 |
|
|
|
-
Allen J, Abbott D, Eskandar J, Bair SM, Haverkos B, Jasem J, Kamdar M, Major A. DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 Jan; 25(1):e26-e33.
Score: 0.054
-
Weisse CS, Melekis K, Cheng A, Konda AK, Major A. Mixed-Methods Study of End-of-Life Experiences of Patients With Hematologic Malignancies in Social Hospice Residential Home Care Settings. JCO Oncol Pract. 2024 Jun; 20(6):779-786.
Score: 0.052
-
Major A, Hammes A, Schmidt MQ, Morgan R, Abbott D, Kamdar M. Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2020 01; 20(1):39-46.
Score: 0.038
-
Major A, Smith DE, Ghosh D, Rabinovitch R, Kamdar M. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis. Cancer. 2020 01 01; 126(1):189-201.
Score: 0.038
-
Major A, Jackson MW, Smith DE, Kamdar M, Rabinovitch R. Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. Leuk Lymphoma. 2019 05; 60(5):1234-1243.
Score: 0.036
-
Major A, Anderson M. Not Just Skin Deep: Distant Metastases from Cutaneous Squamous Cell Carcinoma. Am J Med. 2017 Aug; 130(8):e327-e328.
Score: 0.032
-
Cliff ERS, Pelaez GD, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Allen J, Major A, Sharp J, Epperla N, Gould P, Cherng HJ, Houshyar S, Wallace DS, Lynch RC, Kallam A, Mei MG, Merryman RW, Fleyshman M, Rhodes JM, Kidwell A, Fenske TS, Malakhov N, Mulvey E, Watkins MP, Alhaj Moustafa M, Hilal T, Nowakowski GS, Wang Y, Torka P, Russler-Germain DA. Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma. Clin Cancer Res. 2026 Jan 06; 32(1):159-168.
Score: 0.015
-
Brooks TR, Zabor EC, Bedelu YB, Yang X, Karimi YH, Nedved AN, Wang Y, Dave N, Landsburg DJ, Baron K, Hu B, Trotier DC, Pophali PA, Miller J, Grover N, Reinert C, Major A, Schwarz T, Patel K, Salafian K, Ayers E, Sundaram S, Brody JD, McKenna M, Ryu Tiger YK, Sears-Smith M, Ghosh N, Peterson C, Khan C, Bliven SP, Narkhede M, Gibson A, Kline J, Munoz J, Garza-Morales R, Ho CI, Smith SD, Niu A, Hernandez-Ilizaliturri F, Chinyengetere F, Dave S, Abdel-Razeq N, Moustafa MA, Caimi PF, Hill BT. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025 Oct 30; 146(18):2177-2188.
Score: 0.015
-
Ogamba CF, Joseph A, Adefemi AK, Ezegwui CO, Major A, Jimoh RO, Orhue MO, Ezeanochie MC, Ago BU, Amah LO, Okoh EE, Idahor CO, Ejikem M, Tinworth AC, Zisou C, Lasebikan NN. Factors associated with health-related quality of life and financial toxicity among gynecological cancer patients in Southern Nigeria. Sci Rep. 2025 Jul 31; 15(1):28041.
Score: 0.014
-
Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Geethakumari PR, Hamadani M, Grover N, Epperla N. Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers. Blood Cancer J. 2025 03 26; 15(1):45.
Score: 0.014
-
Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
Score: 0.014
-
Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 07 09; 8(13):3507-3518.
Score: 0.013
-
Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2024 06 01; 109(6):1766-1778.
Score: 0.013
-
Derman BA, Cooperrider J, Rosenblatt J, Avigan DE, Rampurwala M, Barnidge D, Major A, Karrison T, Jiang K, Ramsland A, Kubicki T, Jakubowiak AJ. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
Score: 0.013
-
Kubicki T, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Wróbel T, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Kruk-Kwapisz D, Derman BA, Major A, Jakubowiak AJ, Dytfeld D. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).
Score: 0.013
-
Abdallah M, Akhtar OS, Major A, Mian H, Tsang M, Torka P. Perspectives on geriatric oncology research presented at the 2023 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology report. J Geriatr Oncol. 2024 06; 15(5):101762.
Score: 0.013
-
Mian H, Wildes TM, Vij R, Pianko MJ, Major A, Fiala MA. Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. Blood Cancer J. 2023 05 10; 13(1):76.
Score: 0.012
-
David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Chang J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023 06; 98(6):900-912.
Score: 0.012
-
Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin P. EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma. 2023 05; 64(5):1026-1034.
Score: 0.012
-
Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 01 20; 139(3):413-423.
Score: 0.011
-
Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. N Engl J Med. 2017 07 06; 377(1):89-91.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|